Monte Rosa Therapeutics Inc

NASDAQ:GLUEUnited States

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Contact Information

Headquarters

321 Harrison Avenue, Suite 900BOSTON, MA, United States 02118

Phone

617-949-2643

Fax

302-655-5049

Executives

Non-Executive Independent Chairman of the Board

Andrew Schiff

President, Chief Executive Officer, Director

Markus Warmuth

Chief Operating Officer

Jennifer Champoux

Chief Scientific Officer

Sharon Townson

Chief Medical Officer

Filip Janku